Navigation Links
UTSA/UTHSCSA publish results on bio-threat agent
Date:7/1/2008

San Antonio (June 30, 2008) Researchers at The University of Texas at San Antonio (UTSA) South Texas Center for Emerging Infectious Diseases and The University of Texas Health Science Center at San Antonio (UTHSCSA) have identified a cell type believed to play a role in controlling the early infectious process against Francisella tularensis, a respiratory pathogen and bioterrorism agent that is the cause of tularemia. The findings will be released this week in a journal article in the Proceedings of the National Academy of Sciences.

The organism is considered to be a life-threatening bioterrorism agent by the Centers for Disease Control. Tularemia is an illness caused primarily by bites or scratches from rabbits, rodents and hares. In most cases, the bacterium causes relatively benign fever, chills and headaches that can be treated with antibiotics. However, when spread by aerosol, the organism can cause severe respiratory illness and systemic infections and is associated with a 30-40 percent mortality rate.

"We have found that mast cells, historically associated with allergic conditions and asthma, may also be involved in priming innate and adaptive immunity against tularemia," said Bernard Arulanandam, UTSA College of Sciences immunologist and associate professor of biology. "Our studies show that mast cells can interact with other cells and control the number of bacteria that replicate. This opens up a new dimension into how we look at mast cells against this organism, Francisella tularensis."

In 2005, the Department of Health and Human Services awarded UTSA's South Texas Center for Emerging Infectious Diseases a five-year $6.4 million grant to study tularemia.

Collaborators in the published study include Jyothi Ketavarapu, Annette Rodriguez, Karl Klose, Neal Guentzel, Thomas Forsthuber, Jieh-Juen Yu, Yu Cong, Ashlesh Murthy, and Bernard Arulanandam at UTSA, and Mike Berton with The UTHSCSA.

"I think this journal article shows the quality of the researchers that we have managed to attract to UTSA and we should be proud that important research is taking place on our campus as opposed to at a medical school someplace else," said Karl Klose, executive director of the South Texas Center for Emerging Infectious Diseases. "This is really a move in the right direction towards developing this university into a premier research institution."


'/>"/>

Contact: Marianne Lewis
marianne.lewis@utsa.edu
210-458-5141
University of Texas at San Antonio
Source:Eurekalert

Related biology technology :

1. Results of Study in Pre-School Children Published in Clinical Pediatrics Adds to Support for Importance of Dietary DHA Intake
2. The Protein Tomography(TM) Award Now Published on Sidecs Homepage
3. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
4. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
5. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
6. Springer publishes anthology with the Nanoethics Group
7. New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl)
8. CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal
9. Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics Scientists and Collaborators in Nature Biotechnology
10. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
11. Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):